AbbVie Newsroom

Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $214

Moomoo NewsApr 18 02:40 ET

AbbVie Analyst Ratings

BenzingaApr 17 11:34 ET

Guggenheim Reiterates Buy on AbbVie, Maintains $214 Price Target

BenzingaApr 17 11:34 ET

Citi Maintains AbbVie(ABBV.US) With Buy Rating, Cuts Target Price to $210

Moomoo NewsApr 12 02:31 ET

AbbVie Analyst Ratings

BenzingaApr 9 09:57 ET

Morgan Stanley Adjusts Price Target on AbbVie to $241 From $239, Keeps Overweight Rating

MT NewswiresApr 9 09:42 ET

Wells Fargo Remains a Buy on AbbVie (ABBV)

TipRanksApr 9 06:47 ET

Goldman Sachs Initiates AbbVie(ABBV.US) With Hold Rating, Announces Target Price $194

Moomoo NewsApr 9 02:31 ET

AbbVie Hold Rating: Balancing Strong Immunology Growth With Challenges in Aesthetics, Neuroscience, and Oncology

TipRanksApr 8 20:22 ET

AbbVie Analyst Ratings

BenzingaApr 8 12:09 ET

Goldman Sachs Assumes AbbVie at Neutral, Announces Price Target of $194

BenzingaApr 8 12:09 ET

Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $239

Moomoo NewsApr 8 02:33 ET

Bernstein Keeps Their Hold Rating on AbbVie (ABBV)

TipRanksApr 3 02:47 ET

Erste Group Initiates AbbVie(ABBV.US) With Buy Rating

Moomoo NewsMar 18 02:33 ET

AbbVie: Hold Rating Maintained Amid Strong Skyrizi Sales and Valuation Concerns

TipRanksMar 12 06:31 ET

Berenberg Adjusts Price Target on AbbVie to $195 From $165, Maintains Hold Rating

MT NewswiresMar 12 06:30 ET

Redburn Atlantic Adjusts Price Target on AbbVie to $234 From $216

MT NewswiresMar 10 08:06 ET

AbbVie Is Maintained at Overweight by Wells Fargo

Dow JonesMar 5 10:23 ET

Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $240

Moomoo NewsMar 5 07:31 ET

Wells Fargo Adjusts Price Target on AbbVie to $240 From $210, Keeps Overweight Rating

MT NewswiresMar 5 06:09 ET